Questions as UN agency set to declare Ebola fully eradicated

Thursday January 14 2016

A woman gets vaccinated at a health centre in Conakry on March 10, 2015 during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. A new case of Ebola has been confirmed in Sierra Leone, officials said today, the second case since west Africa celebrated a declared end to the epidemic last week. PHOTO | CELLOU BINANI |

A woman gets vaccinated at a health centre in Conakry on March 10, 2015 during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. Two experimental vaccines against the Ebola virus have shown promise in protecting against the haemorrhagic fever for at least a year. PHOTO | CELLOU BINANI | AFP

More by this Author

MONROVIA, Wednesday

The world will heave a collective sigh of relief when west Africa’s Ebola epidemic is finally declared at an end after claiming more than 11,000 lives over two years.

But with a cure still out of reach, and no vaccine on the market, are we better prepared for next time?

Important lessons were learnt the hard way from the unprecedented devastation and suffering wrought on Liberia, Guinea and Sierra Leone - the countries hardest hit by the outbreak which started in December 2013, say experts.


Epidemiological protocols were improved. At first, many infected people were not quarantined fast enough or given the right type of care.

The World Health Organisation’s (WHO) much-criticised reaction lag led to an overhaul of epidemic response guidelines.

Deployment of medical staff, virus-blocking suits, medicines and other material is likely to happen much faster next time.

“We know how to stop the spread,” Liberia’s chief medical officer Francis Karteh told AFP. “Liberia is no longer at risk like the way it was.”

The WHO is due to declare on Thursday an official end to this outbreak, which infected more than 28,600 people and killed over 11,300.

Before this epidemic, fewer than 2,500 people were known to have been killed by the virus since it was first discovered in 1976.

Dr Karteh said local doctors learnt much from organisations such as Medecins Sans Frontieres (MSF or Doctors Without Borders), the Red Cross and the WHO, which deployed staff to help contain the epidemic.

A key lesson was the need for quick, safe and hygienic burials of people who died from the virus transmitted through body fluids, and speedily tracing those who had been in contact with them.

The new knowledge came in handy after Liberia - declared Ebola-free - had two further flare-ups, successfully stopped in their tracks. “During the first outbreak our doctors and healthcare workers were not (familiar with) the disease,” said Dr Karteh.

“This is why a good number of them (more than 500) died.”


An ironic upside of the outbreak’s massive scale is that it yielded thousands of survivors for medical research.

This led to the discovery that Ebola virus can live for several months in the semen, spinal column and eye fluid of survivors - though the implications and transmission risk are not yet clear.

It was also recently found that survivors can suffer vision problems, hearing loss and joint pain for months after being declared cured.

The scale of the outbreak, and the global scare caused when infected doctors started returning home from west Africa to Europe and the United States, provided impetus for the fast-track development of drugs.

The resulting pharmaceutical scramble yielded several promising vaccine candidates.

But none have yet been tested in general, non-infected populations - the gold standard for proving efficacy.

Similarly, none of the many potential treatments under investigation have so far been proven to work.

Many drug studies started when the epidemic was already declining and there were no longer enough patients for clinical trials.


Nevertheless, many studies have advanced to the point that testing can continue if there is another outbreak.

The frontrunners are ZMapp, a cocktail of three artificial Ebola antibodies made by Mapp Biopharmaceutical in California and Avigan, an antiviral tablet developed by a subsidiary of Japan’s Fujifilm Holdings.

Both were given to infected medical workers, though it is not sure that their survival was due to the treatment.

A lesser-known compound called GS-5734, developed by US-based Gilead Sciences, was given to a Scottish nurse hospitalised with a serious relapse months after her initial recovery. She recovered.

A study released last week concluded that transfusions of blood plasma from survivors - despite sky-high expectations - failed to significantly increase the odds of recovery.

“We learnt a lot during this epidemic,” said Michel Van Herp of MSF.

“The next epidemic will not be as dramatic.” Jean-Francois Delfraissy, French immunologist, said keeping an eye on survivors, and boosting African early alert systems, were crucial to breaking the transmission chain.